Section Arrow
Quote
NCEL.NASDAQ
- NewcelX Ltd.
Quotes are at least 15-min delayed:2026/06/06 18:41 EDT
Regular Hours
Last
 2.93
-0.22 (-6.98%)
Day High 
3.195 
Prev. Close
3.15 
1-M High
3.89 
Volume 
17.19K 
Bid
2.85
Ask
3.6
Day Low
2.842 
Open
3.0703 
1-M Low
2.99 
Market Cap 
16.96M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.31 
20-SMA 3.29 
50-SMA 3.08 
52-W High 7.64 
52-W Low 0.74 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.16/1.13
Enterprise Value
16.96M
Balance Sheet
Book Value Per Share
1.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BCDABioCardia Inc.1.03+0.111+12.08%-- 
BGMSBio Green Med Solution Inc1.5+0.44+41.51%0.3PE
CMNDClearmind Medicine Inc.3.98+1.07+36.77%-- 
ADTXAditxt Inc.0.0621-0.0149-19.35%-- 
RXRXRecursion Pharmaceuticals3.315-0.485-12.76%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.